iCAD (ICAD) Q3 2024 earnings summary

Executive summary

• Achieved Q3 2024 revenue of $4.2 million, up 4% year-over-year, driven by SaaS/cloud transition and global expansion, with 85 deals closed including major contracts with UCSD Health and Charlotte Radiology.

• Annual recurring revenue (ARR) reached $9.3 million, a 10% year-over-year increase, fueled by strong adoption of the ProFound Cloud platform.

• FDA clearance received for ProFound Detection v4.0, offering a 22% improvement in detecting aggressive cancers and an 18% reduction in false positives.

• Completed Xoft business line divestiture, sharpening focus on AI-powered Detection segment.

• Expanded global reach with new regulatory clearances and partnerships in multiple countries.

Financial highlights

• Q3 2024 product revenue rose 14.1% to $2.5 million; services revenue declined 8.9% to $1.7 million due to migration to subscription/cloud.

• Gross profit margin remained strong at 86%, with gross profit of $3.6 million.

• GAAP net loss from continuing operations was $1.8 million ($0.07 per share), compared to $1 million ($0.04 per share) last year.

• Non-GAAP adjusted EBITDA loss was $1.5 million, up from $0.8 million year-over-year.

• Cash and equivalents stood at $18.8 million as of September 30, 2024, with no immediate need for additional funding.

Outlook and guidance

• Transition to SaaS/cloud is expected to flatten or reduce short-term GAAP revenue and cash flow, but will build recurring revenue and backlog for long-term stability.

• Management targets further expansion in underpenetrated US and global markets, supported by new regulatory requirements and global partnerships.